![CRB-401 18-month follow-up: influence of T-cell profile on outcome of ide-cel treatment in myeloma [Video]](https://crowd-funding.givetaxfree.org/wp-content/uploads/2023/09/mp_168524_0_0jpg.jpg)
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, summarizes results from the post hoc 18-month follow-up of the Phase I CRB-401 study (NCT02658929) which investigated the efficacy and safety of idecabtagene vicleucel (ide-cel) treatment in patients with relapsed/refractory (R/R) multiple myeloma. Dr Lin comments on the longer progression-free survival (PFS) observed in patients whose T-cells showed naive stem cell-like characteristics and the influence of prior salvage therapies on T-cell profile. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Medicines: Idecabtagene vicleucel
![Value of MRD status one month after CAR-T therapy in patients with multiple myeloma [Video]](https://crowd-funding.givetaxfree.org/wp-content/uploads/2023/09/mp_168515_0_0jpg.jpg)
CAR-T cell therapies have transformed the treatment landscape of multiple myeloma. In this video, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, shares some insights into the prognostic value of bone marrow measurable residual disease (MRD) status one month after CAR-T cell therapy in patients with multiple myeloma. Dr Lin explains that early MRD negativity is associated with prolonged progression-free survival (PFS), with patients thought to have a higher risk of disease progression if they do not achieve this. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.